CN105189506A - 用于治疗寄生虫疾病的化合物和组合物 - Google Patents
用于治疗寄生虫疾病的化合物和组合物 Download PDFInfo
- Publication number
- CN105189506A CN105189506A CN201380065714.4A CN201380065714A CN105189506A CN 105189506 A CN105189506 A CN 105189506A CN 201380065714 A CN201380065714 A CN 201380065714A CN 105189506 A CN105189506 A CN 105189506A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- pyrazine
- methyl
- imidazo
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *c1cnc(*)cc1 Chemical compound *c1cnc(*)cc1 0.000 description 35
- ZEKBKTMMBLWNGK-UHFFFAOYSA-N CC(C)(C)c1nnn[nH]1 Chemical compound CC(C)(C)c1nnn[nH]1 ZEKBKTMMBLWNGK-UHFFFAOYSA-N 0.000 description 1
- OGDPVERFWFLZHA-UHFFFAOYSA-N CC(C)SC(C)C(C)N Chemical compound CC(C)SC(C)C(C)N OGDPVERFWFLZHA-UHFFFAOYSA-N 0.000 description 1
- ZICRALLMHKILDG-UHFFFAOYSA-N CC(C)c1n[nH]cc1 Chemical compound CC(C)c1n[nH]cc1 ZICRALLMHKILDG-UHFFFAOYSA-N 0.000 description 1
- IHEQAKZPAFNFSA-RWHTWPBISA-N CC1(/C=N\C(\C(N(C)c(cc2)ccc2F)=O)=C/C)NC(c2ccc3[n](C)ncc3c2)=CN1 Chemical compound CC1(/C=N\C(\C(N(C)c(cc2)ccc2F)=O)=C/C)NC(c2ccc3[n](C)ncc3c2)=CN1 IHEQAKZPAFNFSA-RWHTWPBISA-N 0.000 description 1
- SEVQLWITECQUHH-ZHZULCJRSA-N CCCc1ncc(-c(cc2)ccc2-c2nnc[s]2)[n]1/C=C(/C(N(C)C(CC1)=CC=C1Cl)=O)\N Chemical compound CCCc1ncc(-c(cc2)ccc2-c2nnc[s]2)[n]1/C=C(/C(N(C)C(CC1)=CC=C1Cl)=O)\N SEVQLWITECQUHH-ZHZULCJRSA-N 0.000 description 1
- OVRVQGZHQUPWQA-UHFFFAOYSA-N CCOc1cc(N(C)C(C(N=CC2=C3)=CN2C(c2ccc(C(F)(F)F)cc2)=CC3=C)=O)ncc1 Chemical compound CCOc1cc(N(C)C(C(N=CC2=C3)=CN2C(c2ccc(C(F)(F)F)cc2)=CC3=C)=O)ncc1 OVRVQGZHQUPWQA-UHFFFAOYSA-N 0.000 description 1
- OLGOTNLCPQXGLS-UHFFFAOYSA-N CC[n]1ncc(C)c1 Chemical compound CC[n]1ncc(C)c1 OLGOTNLCPQXGLS-UHFFFAOYSA-N 0.000 description 1
- GAKXENQAPIJXRU-JXAWBTAJSA-N CCc1ncc(-c2ccc(C(F)(F)F)cc2)[n]1/C=C(/C(N(C)c1ccc(N(C)C)nc1)=O)\N Chemical compound CCc1ncc(-c2ccc(C(F)(F)F)cc2)[n]1/C=C(/C(N(C)c1ccc(N(C)C)nc1)=O)\N GAKXENQAPIJXRU-JXAWBTAJSA-N 0.000 description 1
- VGBQOAPZAJFNSL-UHFFFAOYSA-N CN(C(C1=C[n]2c(-c3ccnc(Cl)c3)cnc2CC1)=O)c(cc1)ccc1C#N Chemical compound CN(C(C1=C[n]2c(-c3ccnc(Cl)c3)cnc2CC1)=O)c(cc1)ccc1C#N VGBQOAPZAJFNSL-UHFFFAOYSA-N 0.000 description 1
- AMZITDJEKRWENH-UHFFFAOYSA-N CN(C(c(nc1)c[n]2c1ncc2-c(cc1)ccc1C1=NN=CC1)=O)c(cc1)ccc1F Chemical compound CN(C(c(nc1)c[n]2c1ncc2-c(cc1)ccc1C1=NN=CC1)=O)c(cc1)ccc1F AMZITDJEKRWENH-UHFFFAOYSA-N 0.000 description 1
- DYCDLWSHAFQOQS-UHFFFAOYSA-N CN(C)CCN(C(c(nc1)c[n]2c1ncc2-c1ccc(C(F)(F)F)cc1)=O)C(C=C1)=CC1C#N Chemical compound CN(C)CCN(C(c(nc1)c[n]2c1ncc2-c1ccc(C(F)(F)F)cc1)=O)C(C=C1)=CC1C#N DYCDLWSHAFQOQS-UHFFFAOYSA-N 0.000 description 1
- NPDBDURRDSIKQD-UHFFFAOYSA-N CN(C)c(nc1)ccc1-c1cnc2[n]1cc(C(N(C)c(cn1)ccc1Cl)=O)nc2 Chemical compound CN(C)c(nc1)ccc1-c1cnc2[n]1cc(C(N(C)c(cn1)ccc1Cl)=O)nc2 NPDBDURRDSIKQD-UHFFFAOYSA-N 0.000 description 1
- SOXRHKNYYSNEAZ-UHFFFAOYSA-N CN(Cc(nc1)c[n]2c1ncc2Br)c(cc1)ccc1C#N Chemical compound CN(Cc(nc1)c[n]2c1ncc2Br)c(cc1)ccc1C#N SOXRHKNYYSNEAZ-UHFFFAOYSA-N 0.000 description 1
- YDYWIJGHXKMAHB-UHFFFAOYSA-N CNC(C(CC1)=CC=C1c1cnc2[n]1cc(C(N1c(ccc(F)c3)c3OCC1)=O)nc2)=O Chemical compound CNC(C(CC1)=CC=C1c1cnc2[n]1cc(C(N1c(ccc(F)c3)c3OCC1)=O)nc2)=O YDYWIJGHXKMAHB-UHFFFAOYSA-N 0.000 description 1
- KFKXBRFAEDEHBI-UHFFFAOYSA-N CNC(c1ccc(C2N(CC(C(N(CI)C(C=C3)=CCC=C3Cl)=O)N=C3)C3=NC2)cc1)=O Chemical compound CNC(c1ccc(C2N(CC(C(N(CI)C(C=C3)=CCC=C3Cl)=O)N=C3)C3=NC2)cc1)=O KFKXBRFAEDEHBI-UHFFFAOYSA-N 0.000 description 1
- HLYMRJOVXOPJHQ-LCYFTJDESA-N COC(/C(/N)=C/[n]1c(-c2ccc(C(F)(F)F)cc2)cnc1C1CC1)=O Chemical compound COC(/C(/N)=C/[n]1c(-c2ccc(C(F)(F)F)cc2)cnc1C1CC1)=O HLYMRJOVXOPJHQ-LCYFTJDESA-N 0.000 description 1
- ROBQKMKHRZINIJ-UHFFFAOYSA-O C[NH+]1C2C1CC2 Chemical compound C[NH+]1C2C1CC2 ROBQKMKHRZINIJ-UHFFFAOYSA-O 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N C[n]1cncc1 Chemical compound C[n]1cncc1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- UQFQONCQIQEYPJ-UHFFFAOYSA-N C[n]1nccc1 Chemical compound C[n]1nccc1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 1
- HHPIVZLMDVERHJ-UHFFFAOYSA-N Cc(nc1)cnc1N(C)C(c(nc1)c[n]2c1ncc2-c1ccc(C(F)(F)F)cc1)=O Chemical compound Cc(nc1)cnc1N(C)C(c(nc1)c[n]2c1ncc2-c1ccc(C(F)(F)F)cc1)=O HHPIVZLMDVERHJ-UHFFFAOYSA-N 0.000 description 1
- LSZQMSSIUQNTDX-UHFFFAOYSA-N Cc1ccn[n]1C Chemical compound Cc1ccn[n]1C LSZQMSSIUQNTDX-UHFFFAOYSA-N 0.000 description 1
- PEUUDVCRSCULKR-UHFFFAOYSA-N Cc1cnc(C2N(C=C(C(N(C)c(cc3)csc3C#N)=O)NC3)C3=NC2)cc1 Chemical compound Cc1cnc(C2N(C=C(C(N(C)c(cc3)csc3C#N)=O)NC3)C3=NC2)cc1 PEUUDVCRSCULKR-UHFFFAOYSA-N 0.000 description 1
- MJVZSRZTBDMYLX-UHFFFAOYSA-N Nc(ccc(Cl)n1)c1Cl Chemical compound Nc(ccc(Cl)n1)c1Cl MJVZSRZTBDMYLX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261728024P | 2012-11-19 | 2012-11-19 | |
| US61/728,024 | 2012-11-19 | ||
| PCT/US2013/070623 WO2014078813A1 (en) | 2012-11-19 | 2013-11-18 | Compounds and compositions for the treatment of parasitic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105189506A true CN105189506A (zh) | 2015-12-23 |
Family
ID=49667633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380065714.4A Pending CN105189506A (zh) | 2012-11-19 | 2013-11-18 | 用于治疗寄生虫疾病的化合物和组合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150291598A1 (https=) |
| EP (1) | EP2920177A1 (https=) |
| JP (1) | JP2016500073A (https=) |
| CN (1) | CN105189506A (https=) |
| WO (1) | WO2014078813A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110168093A (zh) * | 2017-09-12 | 2019-08-23 | 广州中科蓝华生物科技有限公司 | 一种转染细胞内寄生虫的试剂盒及其应用 |
| CN110809577A (zh) * | 2017-06-30 | 2020-02-18 | 雷沃医疗有限公司 | 腺苷a2a受体的调节剂 |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014078813A1 (en) * | 2012-11-19 | 2014-05-22 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| CN105164124B (zh) | 2012-11-19 | 2017-03-15 | 诺华股份有限公司 | 用于治疗寄生虫疾病的化合物和组合物 |
| RU2725979C2 (ru) * | 2014-06-25 | 2020-07-08 | Ф. Хоффманн-Ля Рош Аг | ИМИДАЗО[1,2-а]ПИРАЗИН-1-ИЛ-БЕНЗАМИДЫ ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ |
| CA2969090C (en) | 2014-12-23 | 2023-05-02 | Novartis Ag | Triazolopyrimidine compounds and uses thereof |
| CN104610229B (zh) * | 2015-01-21 | 2017-01-18 | 上海皓元生物医药科技有限公司 | 一种是atp竞争性小分子akt抑制剂a443654的合成方法 |
| JP7042812B2 (ja) | 2016-06-20 | 2022-03-28 | ノバルティス アーゲー | トリアゾロピリミジン化合物の結晶形態 |
| WO2017221100A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Imidazopyrimidine compounds useful for the treatment of cancer |
| WO2017221092A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| GB201700692D0 (en) * | 2017-01-16 | 2017-03-01 | Salvensis | Novel compounds and their use in the treatment of schistosomiasis |
| EP3617207B1 (en) * | 2017-04-27 | 2023-06-28 | Nihon Nohyaku Co., Ltd. | Condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound or the salt, and method for using the insecticide |
| US11584744B2 (en) * | 2017-06-23 | 2023-02-21 | University Of Washington | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them |
| EP3746071A4 (en) | 2018-01-29 | 2021-09-01 | Merck Patent GmbH | GCN2 INHIBITORS AND THEIR USES |
| US10239885B1 (en) | 2018-06-18 | 2019-03-26 | Avista Pharma Solutions, Inc. | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist |
| GB201811695D0 (en) * | 2018-07-17 | 2018-08-29 | Salvensis | Compounds for use in the treatment of fascioliasis |
| SG11202012616RA (en) | 2018-08-21 | 2021-02-25 | Kyorin Pharmaceutical Co Ltd | Bicyclic heteroaromatic ring derivative |
| AU2019395201A1 (en) | 2018-12-06 | 2021-05-20 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
| US11512088B2 (en) | 2019-01-30 | 2022-11-29 | Avista Pharma Solutions, Inc. | Synthetic process and intermediates |
| WO2020160075A1 (en) | 2019-01-30 | 2020-08-06 | Avista Pharma Solutions, Inc. | Chemical compounds |
| BR112022007404A2 (pt) | 2019-10-21 | 2022-07-05 | Novartis Ag | Compostos e composições para o tratamento de doenças parasíticas |
| WO2024022910A1 (en) | 2022-07-26 | 2024-02-01 | Syngenta Crop Protection Ag | 1-[1-[2-(pyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]-3-[2,4-dichloro-5-phenyl]urea derivatives and similar compounds as pesticides |
| EP4695245A1 (en) * | 2023-04-13 | 2026-02-18 | Syngenta Crop Protection AG | Imidazo[1,2-a]pyridine derivatives |
| PY2426847A (es) * | 2023-04-13 | 2025-03-20 | Syngenta Crop Protection Ag | Derivados bicíclicos de imidazo |
| TW202446263A (zh) * | 2023-04-13 | 2024-12-01 | 瑞士商先正達農作物保護股份公司 | 殺真菌組成物 |
| WO2024213653A1 (en) * | 2023-04-13 | 2024-10-17 | Syngenta Crop Protection Ag | Imidazo[1,2-a]pyridine derivatives |
| AR132352A1 (es) * | 2023-04-13 | 2025-06-18 | Syngenta Crop Protection Ag | Derivados de imidazo[1,2-a]pirazina |
| WO2024213650A1 (en) * | 2023-04-13 | 2024-10-17 | Syngenta Crop Protection Ag | Imidazo[1,2-a]pyridine derivatives |
| WO2026018203A1 (en) * | 2024-07-19 | 2026-01-22 | Novartis Ag | Aminoisoquinoline compounds and methods of using thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| CN101622001A (zh) * | 2007-01-26 | 2010-01-06 | Irm责任有限公司 | 作为激酶抑制剂用于治疗疟原虫相关疾病的嘌呤化合物和组合物 |
| TWI421252B (zh) * | 2009-07-09 | 2014-01-01 | Irm Llc | 用於治療寄生蟲疾病之化合物及組合物 |
| WO2014078813A1 (en) * | 2012-11-19 | 2014-05-22 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
-
2013
- 2013-11-18 WO PCT/US2013/070623 patent/WO2014078813A1/en not_active Ceased
- 2013-11-18 JP JP2015543098A patent/JP2016500073A/ja active Pending
- 2013-11-18 CN CN201380065714.4A patent/CN105189506A/zh active Pending
- 2013-11-18 US US14/443,604 patent/US20150291598A1/en not_active Abandoned
- 2013-11-18 EP EP13795980.5A patent/EP2920177A1/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110809577A (zh) * | 2017-06-30 | 2020-02-18 | 雷沃医疗有限公司 | 腺苷a2a受体的调节剂 |
| CN110168093A (zh) * | 2017-09-12 | 2019-08-23 | 广州中科蓝华生物科技有限公司 | 一种转染细胞内寄生虫的试剂盒及其应用 |
| CN110168093B (zh) * | 2017-09-12 | 2023-08-15 | 中科蓝华(广州)生物医药技术有限公司 | 一种转染细胞内寄生虫的试剂盒及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150291598A1 (en) | 2015-10-15 |
| EP2920177A1 (en) | 2015-09-23 |
| WO2014078813A1 (en) | 2014-05-22 |
| JP2016500073A (ja) | 2016-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105189506A (zh) | 用于治疗寄生虫疾病的化合物和组合物 | |
| TWI869519B (zh) | Sos1抑制劑 | |
| TWI868441B (zh) | 非環氧氮呯化合物及其用途 | |
| US20240025919A1 (en) | Aza-tetracyclic oxazepine compounds and uses thereof | |
| CN102203067B (zh) | Hedgehog通路调节剂 | |
| WO2023064857A1 (en) | Quinoline compounds as inhibitors of kras | |
| JP6298472B2 (ja) | 寄生虫病の処置のための化合物および組成物 | |
| JP2025535367A (ja) | ６－アザ部分を含むオキサゼピン化合物およびその使用 | |
| CN115485278A (zh) | 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法 | |
| CN108026105B (zh) | TGFβ受体拮抗剂 | |
| TW201522342A (zh) | 用於治療寄生蟲疾病之化合物及組合物 | |
| JP2013501002A (ja) | Ｓｙｋキナーゼ阻害剤としての化合物および組成物 | |
| KR20170075756A (ko) | 카르바졸 유도체 | |
| TWI879771B (zh) | 三環類化合物及其用途 | |
| JP2020537692A (ja) | ヘテロ環式化合物、ヘテロ環式化合物を含む組成物、及びその使用方法 | |
| WO2014151630A2 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| CN106029666B (zh) | 作为原生动物蛋白酶体抑制剂用于治疗寄生虫疾病例如利什曼病的[1,2,4]三唑并[1,5-a]嘧啶衍生物 | |
| CN107922407A (zh) | 呼吸道合胞病毒抑制剂 | |
| TW202216712A (zh) | 一種高活性的ｈｐｋ１激酶抑制劑 | |
| CN114127080B (zh) | 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法 | |
| CN112209925A (zh) | Ret选择性抑制剂及其制备方法和用途 | |
| TWI768781B (zh) | 轉化生長因子－β受體抑制劑 | |
| WO2023169170A1 (zh) | 作为shp2抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法 | |
| CN119053596A (zh) | 作为激酶抑制剂的杂环化合物、其组合物及使用方法 | |
| HK40099028A (zh) | 氧氮杂䓬化合物及其在癌症治疗中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20180302 |